ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
Latest From ASCO
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication.
Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.
ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.
Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.
Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.